{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:26:53Z","timestamp":1790879213705,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,6,15]],"date-time":"2006-06-15T00:00:00Z","timestamp":1150329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Mastocytosis is characterized by the abnormal proliferation of mast cells in 1 or more organs. In most patients, a mutation is present in the gene for <jats:italic>C\u2010KIT<\/jats:italic>, resulting in deregulation of the c\u2010kit receptor. Imatinib mesylate is a potent inhibitor of c\u2010kit receptor tyrosine kinase activity. Therefore, the authors evaluated the efficacy and safety of imatinib mesylate as treatment for patients with systemic mastocytosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Patients with systemic mastocytosis received imatinib mesylate orally at a dose of 400 mg once daily for 3 to 6 months. Low doses of prednisone were added during the first 2 weeks. Endpoints were reductions in serum tryptase, urinary N\u2010methylhistamine excretion, skin lesions, the number of mast cells in bone marrow sections, hepatomegaly and\/or splenomegaly, and symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Of 14 patients who were included in the study, 11 patients had the D816V mutation. One patient expressed the <jats:italic>FIP1L1<\/jats:italic>\u2010<jats:italic>PDGFR\u2010\u03b1<\/jats:italic> rearrangement gene. In 2 patients, no mutation was found. In 10 patients, serum tryptase levels decreased &gt;20%. In all patients, urinary N\u2010methylhistamine excretion was reduced. In 8 of 13 evaluable patients, the number of mast cells in the bone marrow decreased. Skin symptoms diminished in 5 of 9 patients. Hepatosplenomegaly improved in 3 of 6 patients. Symptoms decreased in 8 of 13 patients. In all patients who had the D816V mutation, reductions in \u22652 endpoints were achieved. In the patient who expressed the <jats:italic>FIP1L1<\/jats:italic>\u2010<jats:italic>PDGFR\u2010\u03b1<\/jats:italic> rearrangement gene, a complete response was attained. In general, imatinib mesylate was tolerated well.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>Imatinib mesylate was effective in patients with systemic mastocytosis, including those who had the D816V mutation. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21996","type":"journal-article","created":{"date-parts":[[2006,6,15]],"date-time":"2006-06-15T12:10:10Z","timestamp":1150373410000},"page":"345-351","source":"Crossref","is-referenced-by-count":125,"title":["Imatinib mesylate in the treatment of systemic mastocytosis"],"prefix":"10.1002","volume":"107","author":[{"given":"Helga J.","family":"Droogendijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke J. C.","family":"Kluin\u2010Nelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap J.","family":"van Doormaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold P.","family":"Oranje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan A.","family":"van de Loosdrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L. A.","family":"van Daele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,5]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202273260912"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07056-0"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202273260907"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02131.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1699"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101253440415"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70301-4"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00039-X"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116761"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.23.10560"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0396-312"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.4.1609"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02783.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00046-7"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00028-5"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.577"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441404"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1741"},{"key":"e_1_2_5_22_2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c\u2010kit tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich MC","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14115-3"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1627"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198312293092603"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/00015550152572912"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21996","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:24:20Z","timestamp":1760271860000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21996"}},"subtitle":["A phase II trial"],"short-title":[],"issued":{"date-parts":[[2006,7,5]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,7,15]]}},"alternative-id":["10.1002\/cncr.21996"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21996","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,5]]}}}